Wednesday, October 7, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleNasdaq· May 12, 2026

Weak Stocks and Crude Oil Strength Lift the Dollar

View original at nasdaq.com
Weak Stocks and Crude Oil Strength Lift the Dollar The dollar index (DXY00) on Tuesday rose by +0.34%…
Opening lines of the source · Nasdaq · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The United States has an inflation problem

    60% confidence
  • Swaps price an 87% chance of a +25bp ECB rate hike at the next policy meeting on June 11

    60% confidence
  • Markets price a 75% chance of a 25bp BOJ rate hike at the next policy meeting on June 16

    60% confidence
  • The current US-Iran ceasefire is on 'life support'

    60% confidence
  • Inflation risks in the Eurozone are worsening, pointing toward an ECB interest rate hike in June

    60% confidence
  • The worst part of the April CPI report is services inflation

    60% confidence
  • It is quite possible the BOJ will raise the policy interest rate from the next meeting onward, even amid ongoing Middle East uncertainty

    60% confidence
  • Swaps markets discount 4% odds of a 25bp rate cut at the next FOMC meeting on June 16-17

    60% confidence
  • Japan imports more than 90% of its energy needs, making it vulnerable to crude oil price increases

    60% confidence
  • Current conditions point to an ECB interest rate hike in June

    60% confidence
  • The Federal Reserve must think about how to break the chain of escalating inflation

    60% confidence
  • US April CPI rose +3.8% y/y, the fastest pace in almost three years; core CPI rose +2.8% y/y, the largest increase in six months

    60% confidence
  • PBOC gold reserves rose +260,000 troy ounces to 74.64 million troy ounces in April — the largest monthly increase in a year and the 18th consecutive monthly increase

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com